Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-01-11 00:00:00 ET · period of report 2024-01-09 · accession 0001610717-24-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-11 | 2024-01-09 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $4.59 | +7,417 | 9,331 | +388% | +$34.0K |
| DT | 2024-01-11 | 2024-01-09 | ANTX | Krause Kevin Michael | Chief Strategy Off | S - Sale+OE | $20.14 | -7,417 | 1,914 | -79% | -$149.4K |
| DMT | 2024-01-11 | 2024-01-09 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $0.00 | -7,417 | 26.8K | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-09 | M | A | 2,417 | $0.42 | 4,331 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-09 | S | D | 7,417 | $20.14 | 1,914 | D | — | — | (F2) Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-01-09 | M | A | 5,000 | $6.60 | 9,331 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2024-01-09 | M | D | 2,417 | $0.00 | 49,868 | D | $0.42 · — to 2030-01-22 | 2,417 Common Stock | (F3) The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date. |
| 5 | Derivative | Stock Option (right to buy) | 2024-01-09 | M | D | 5,000 | $0.00 | 26,832 | D | $6.60 · — to 2031-04-29 | 5,000 Common Stock | (F4) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date. |